Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 178Leukemia 170Recurrence 163Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Interventions

toripalimab 2Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Advanced Lung Cancer × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT05000684 2025-02-20

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
67 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡